Benjamin Daelken

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Immunotherapy Treatments. Top assignees: Biotest Ag, Immunogen, Inc., Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin Daelken. Retrieved from https://idiyas.com/inventor/benjamin-daelken

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 62(Granted Patents)

Company Filing History:

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus

patents

4. 1 out of 1,272

Dana-Farber-Cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Immunoconjugates

CD138

Antibodies

Systemic Lupus Erythematosus

Psoriasis

Cytotoxicity

Therapeutic Agents

Disease Treatment

Antibody Sequencing

Tumor Targeting

Pneumonia Treatment

Humanized Antibodies

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12186391 - Treatment of severe community acquired pneumonia (2025-01-07),

2. 11517621 - Treatment of severe community acquired pneumonia (2022-12-06),

3. 10918715 - Treatment of severe community acquired pneumonia (2021-02-16),

4. 10117932 - Uses of immunoconjugates targeting CD138 (2018-11-06),

5. 9995733 - Agents for treating disease (2018-06-12),

6. 9605066 - Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) (2017-03-28),

7. 9550831 - Method for treating psoriasis (2017-01-24),

8. 9540436 - Use of antibodies for detection of IL-10 (2017-01-10),

9. 9512226 - Agent for treating disease (2016-12-06),

10. 9446146 - Methods and agents for improving targeting of CD138 expressing tumor cells (2016-09-20),

11. 9387261 - Immunoconjugates targeting CD138 and uses thereof (2016-07-12),

12. 9334325 - Method for treating psoriasis (2016-05-10),

13. 9289509 - Uses of immunoconjugates targeting CD138 (2016-03-22),

14. 9221914 - Agents targeting CD138 and uses thereof (2015-12-29),

15. 9011864 - Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates (2015-04-21),

Title: Inventor Benjamin Daelken - Revolutionizing Technology in Frankfurt am Main

Introduction: Benjamin Daelken is a visionary inventor based in Frankfurt am Main, Germany, known for his groundbreaking contributions to the field of technology.

Latest Patents: Benjamin Daelken holds several patents in the areas of artificial intelligence, renewable energy, and sustainable transportation, showcasing his commitment to innovation and sustainability.

Career Highlights: With a career spanning over two decades, Benjamin Daelken has worked with leading tech companies to develop cutting-edge solutions that have revolutionized industries worldwide. His expertise in merging technology with environmental consciousness has earned him recognition as a pioneer in his field.

Collaborations: Throughout his career, Benjamin Daelken has collaborated with top researchers, engineers, and scientists to bring his inventions to life. His ability to work across disciplines has led to the creation of innovative products that have had a lasting impact on society.

Conclusion: Benjamin Daelken's passion for innovation and his dedication to creating a more sustainable future through technology make him a standout figure in the world of inventors. His work continues to inspire and shape the technological landscape for years to come.

Profile summary based on public USPTO records.